Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2003
02/20/2003US20030036199 Kit for use in the diagnosis and treatment of cancer
02/20/2003US20030036175 Depletion or removal of endotoxins from solution; obtain solution, incubate with chromatographic column, elute, recover endotoxin free solution
02/20/2003US20030036112 Nucleotide sequences coding polypeptide for use in the treatment and diagnosis of nervous system and tumor disorders
02/20/2003US20030036103 Methods and compositions for diagnosis and treatment of vascular conditions
02/20/2003US20030036078 P5CRs as modifiers of the p53 pathway and methods of use
02/20/2003US20030036076 CADs as modifiers of the p53 pathway and methods of use
02/20/2003US20030035853 Antiinflammatory agents, analgesics; fatty acid mixture and plant extracts
02/20/2003US20030035851 Administering plant extract
02/20/2003US20030035850 Hemorrhoidal compositions and method of use
02/20/2003US20030035847 Acid mixture; anticancer, antitumor agents
02/20/2003US20030035846 Applying magnetic, electric force
02/20/2003US20030035837 Mixture of drug with retarder; sustained release
02/20/2003US20030035836 Oral controlled release pharmaceutical composition for once-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases
02/20/2003US20030035835 Protective overcoatings
02/20/2003US20030035832 Compression of drug and adjuvant
02/20/2003US20030035831 Pharmaceutical compositions for buccal delivery of pain relief medications
02/20/2003US20030035830 Method of administering liposomal encapsulated taxane
02/20/2003US20030035829 Liposomal compositions for the delivery of nucleic acid catalysts
02/20/2003US20030035828 Antiallergens; sustained release; transdermal administering
02/20/2003US20030035819 Skin care composition that mediates cell to cell communication
02/20/2003US20030035813 Immunological treatment methods and agents
02/20/2003US20030035812 Administering vaccine
02/20/2003US20030035801 Stimulating neutrophil function to treat inflammatory bowel disease
02/20/2003US20030035800 Glycosylated humanized B-cell specific antibodies
02/20/2003US20030035795 Methods for treating or reducing the risk of pain and inflammatory disorders by administering inhibitors of activated thrombin activatable fibrinolysis inhibitor
02/20/2003US20030035794 Gene-therapeutic nucleic acid construct, production of same and use of same in the treatment of heart disorders
02/20/2003US20030035792 Recombinant MVA virus, and the use thereof
02/20/2003US20030035788 Method for use of IGF-binding protein for selective sensitization of target cells in vivo
02/20/2003US20030035787 Polyanhydrides with biologically active degradation products
02/20/2003US20030035785 Skin protection composition
02/20/2003US20030035776 Drug particle in aerosol
02/20/2003US20030035775 Inhalation administering; mixture of drug and solvent
02/20/2003US20030034264 Prefilled injector package and sterilizing or disinfecting method therefor
02/20/2003DE20214827U1 Composition useful as dietetic food, nutritional supplement or medicament for enhancing sports performance comprises L-carnitine and omega-3 fatty acids
02/20/2003CA2810339A1 Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia
02/20/2003CA2701551A1 Polysaccharide-containing compositions and use thereof
02/20/2003CA2607992A1 Bicyclic compound, production and use thereof
02/20/2003CA2462200A1 Peptidomimetics of biologically active metallopeptides
02/20/2003CA2459071A1 Use of inhibitors of heparin-binding epidermal growth factor or inhibitors of its receptors for the preparation of drugs useful for treating myeloma
02/20/2003CA2457624A1 Nutrient therapy for immuno-compromised patients
02/20/2003CA2457622A1 Kavalactone compositions and methods of use
02/20/2003CA2457433A1 Novel alpha adrenergic agents
02/20/2003CA2457314A1 Percutaneous absorption preparations
02/20/2003CA2456965A1 A medicine for osteoarthritis
02/20/2003CA2456939A1 Carbonic anhydrase inhibitors
02/20/2003CA2456928A1 Cellular virus receptors and methods of use
02/20/2003CA2456910A1 Drugs for treatment of cerebral injury and methods of use thereof
02/20/2003CA2456833A1 Polysaccharide-containing compositions and use thereof
02/20/2003CA2456754A1 Benzazepine derivative, process for producing the same, and use
02/20/2003CA2456744A1 Adenosine a3 receptor agonists
02/20/2003CA2456720A1 Asymmetric synthesis of kavalactones
02/20/2003CA2456713A1 Improved pharmaceutical composition containing a ppar alpha agent and a process for preparing it
02/20/2003CA2456706A1 Drug release system for controlled therapy
02/20/2003CA2456599A1 Spiro compounds
02/20/2003CA2456594A1 Preventives/remedies for cholinergic neuropathy
02/20/2003CA2456553A1 Compounds which mimic the chemical and biological properties of discodermolide
02/20/2003CA2456549A1 The treatment of lipodystrophy
02/20/2003CA2456533A1 Histone deacetylase enzyme-inhibiting derivatives of hydroxamic acid as new cytokine synthesis-inhibiting anti-inflammatory drugs
02/20/2003CA2456523A1 C-2' methylated derivatives of paclitaxel for use as antitumour agents
02/20/2003CA2456369A1 Proteins associated with cell growth, differentiation, and death
02/20/2003CA2456328A1 Complexes of a short cpg-containing oligonucleotide bound to the surface of a solid phase microcarrier and methods for use thereof
02/20/2003CA2456322A1 Compositions and methods to prevent abuse of opioids
02/20/2003CA2456291A1 Hydroxamic acid derivatives
02/20/2003CA2456288A1 Fatty acid compounds, preparation and uses thereof
02/20/2003CA2456255A1 Protected 3.5-dihydroxy-2.2-dimethyl-valeroamides for the synthesis of epothilone and derivatives and method for the production and use thereof
02/20/2003CA2456250A1 Arylsulfonyl derivatives with 5-ht6 receptor affinity
02/20/2003CA2456175A1 Benzoquinone ansamycins
02/20/2003CA2456159A1 Lipid blends and food products containing oleic fatty acid and omega-6 fatty acids, designed to increase the intramyocellular lipid level
02/20/2003CA2456144A1 A group of novel anti-cancer compounds with specific structure
02/20/2003CA2456124A1 Substituted 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzo[c]fluorene-6-carboxylic acid derivatives serving as nmda antagonists
02/20/2003CA2456103A1 Salts of substituted 1, 2, 3, 4-tetrahydroquinoline-2-carboxylic acid derivatives
02/20/2003CA2456052A1 Surfactant compounds and uses thereof
02/20/2003CA2456034A1 Sustained-release medicines
02/20/2003CA2456030A1 Hypoglycemic agent
02/20/2003CA2455962A1 G protein-coupled receptor assay
02/20/2003CA2455871A1 Substituted pyridin-4-ones and their use as gonadotropin-releasing hormone receptor antagonists.
02/20/2003CA2455861A1 Sulfonamide derivatives as gamma secretase inhibitors
02/20/2003CA2455761A1 Artichoke leaf extracts
02/20/2003CA2455759A1 Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
02/20/2003CA2455754A1 Amine derivatives
02/20/2003CA2455631A1 Aminoisoxazole derivatives active as kinase inhibitors
02/20/2003CA2455585A1 Compounds for treating anhedonia
02/20/2003CA2455498A1 Antisense modulation of apolipoprotein(a) expression
02/20/2003CA2455452A1 Stable and bioavailable iron fortified beverages
02/20/2003CA2455420A1 Compositions and methods to prevent abuse of opioids
02/20/2003CA2455336A1 Peptides that bind to atherosclerotic lesions
02/20/2003CA2454648A1 Irinotecan for treatment of cancer
02/20/2003CA2454643A1 Methods for the treatment of cancer with irinotecan based on cyp3a5
02/20/2003CA2454640A1 Methods for treatment of cancer using irinotecan based on ugt1a1
02/20/2003CA2454637A1 Use of irinotecan for improved treatment of cancer based on mdr1
02/20/2003CA2454627A1 Methods for improved treatment of cancer with irinotecan based on mrp1
02/20/2003CA2454519A1 Hprp4s as modifiers of the p53 pathway and methods of use
02/20/2003CA2454514A1 Sphks as modifiers of the p53 pathway and methods of use
02/20/2003CA2454417A1 Novel benzo-fused heterocycles as endothelin antagonists
02/20/2003CA2454173A1 Stabilized oral suspension formulation
02/20/2003CA2454081A1 Certain substituted polyketides, pharmaceutical compositions containing them and their use in treating tumors
02/20/2003CA2454072A1 Crystalline forms of fluvastatin sodium
02/20/2003CA2453884A1 Micronutrient phosphates as dietary and health supplements
02/20/2003CA2453537A1 Therapeutic 1h-pyrido¬4,3-b|indoles
02/20/2003CA2453506A1 Pramipexole as an anticonvulsant
1 ... 5558 5559 5560 5561 5562 5563 5564 5565 5566 5567 5568 5569 5570 5571 5572 5573 5574 5575 5576 5577 5578 ... 7860